AKT1 and neoplasm: We previously demonstrated the anticancer effect of Tranilast against EC by antagonizing TRPV2, which is responsible for promoting EC tumorigenesis via the HSP70/27 and PI3K/Akt/mTOR pathways; the result also showed no off-target cytotoxicity, especially against non-tumor cells and tissues [16].